U.S. stocks were mixed Thursday following a selloff in Treasury bonds, as the 30-year yield topped the 3% mark. The S&P 500 Index lost 0.1%, the Dow Jones Industrial Average edged 0.1% higher, while the Nasdaq Composite gave back 0.4%.
Plenty of tech giants made headlines with their quarterly results after hours, while other such as Amgen, Inc. (NASDAQ:AMGN), Edwards Lifesciences Corp (NYSE:EW) and Motorola Solutions Inc (NYSE:MSI) reported as well.
Here’s what you should know ahead of Friday’s action:
Amgen, Inc. (AMGN)
Amgen shares fell as the company reported for its fourth quarter and fiscal 2017.
The company posted a loss of $4.26 billion, amounting to $5.89 per share, below the year-ago profit of $1.94 billion, or $2.54 per share. On an adjusted basis, Amgen earned $2.89 per share, below the FactSet projection of $5.85 billion.
Revenue came in at $5.8 billion, falling 2.85% compared to the year-ago quarter. Analysts polled by FactSet were calling for a consensus estimate of $5.85 billion. Amgen was hit with a $6.1 billion charge related to the U.S. tax reform.
A number of its medications sold worse than expected, including Repatha, Aranesp, Sensipar, Xgeva, Vectibix and Blincyto. Others beat the FactSet consensus, such as Neulasta, Enbrel, Prolia, Epogen, Kyprolis, Nplate and Neupogen
For fiscal 2018, Amgen predicts it will rake in between $21.8 billion and $22.8 billion in revenue, below the FactSet outlook of $22.86 billion. It sees earnings in the range of $12.60 to $13.70 per share, below the FactSet consensus of $12.71 per share.
AMGN stock fell 2.5% after the bell Thursday.
Edwards Lifesciences Corp (EW)
Edward Lifesciences hiked higher as the company reported on its latest period.
It was a solid fourth quarter for the Irvine, California-based company, which saw its net income reach $35.7 million, or 17 cents per share to close out a successful fiscal 2017.
Edward Lifesciences brought in adjusted earnings of roughly 94 cents per share for the period, which was stronger than the average estimate of Zacks Investment Research of 90 cents per share.
On the revenue front, the medical device manufacturer raked in $888.5 million. The figure came in ahead of the Wall Street consensus estimate of $862.9 million, according to data compiled by Zacks.
Fourth-quarter earnings for Edward Lifesciences declined 77% compared to the year-ago quarter, due to a charge related to the U.S. tax reform. Adjusted earnings grew 25% year-over-year.
Full-year earnings gained 10%, while adjusted earnings grew 31% year-over-year. Revenue was higher by 16% for both the fourth quarter and the full year. Edward Lifesciences increased its forecast for fiscal 2018 as well.
EW stock gained 3.7% after hours yesterday.
Motorola Solutions Inc (MSI)
Motorola Solutions reported on its fourth quarter Thursday.
The company posted a net loss of $575 million, or $3.56 per share, below the year-ago earnings of $243 million, or $1.43 per share. The company was hit with a $5.50 a share charged linked to the new tax laws.
On an adjusted basis, Motorola Solutions earned $2.10 per share, topping the Wall Street consensus estimate of $2.04 per share, according to FactSet.
Its revenue came in at $1.96 billion, gaining 4.26% year-over-year. The figure came in ahead of analysts’ projections of $1.94 billion, according to data compiled by FactSet.
For its first quarter of fiscal 2018, Motorola Solutions predicts earnings in the range of 83 to 88 cents per share, while revenue is slated to grow 7%. Analysts polled by FactSet are calling for earnings of 80 cents per share and revenue growth of 4%.
Full-year adjusted earnings are slated to surge to $6.50 to $6.65 per share, while revenue is projected to gain 5% year-over-year. Wall Street’s consensus estimate called for full-year earnings of $5.96 per share and revenue growth of 3%.
MSI stock wafted up 1.6% after hours Thursday.
As of this writing, Karl Utermohlen did not hold a position in any of the aforementioned securities.